Nurix Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nurix Therapeutics (NRIX).

Price Target Range — 10 Quarters

Analyst Consensus — 19 Analysts

18Buy

1Hold

Consensus RatingBuy# Analysts19Avg. Consensus PT$32Upside to Avg. PT+26.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 10, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$33→$36
Aug 4, 2026	Needham	Gil Blum	Maintained	Buy	$34
Jul 28, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$36→$38
Jul 22, 2026	UBS	David Dai	PT Raise	Buy	$23→$31
Jul 13, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$30→$34
Jul 10, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$32→$34
Jul 10, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$30→$33
Jul 10, 2026	Stifel	Stephen Willey	PT Raise	Buy	$34→$40
Jul 10, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$32
Jul 10, 2026	Needham	Gil Blum	Maintained	Buy	$34
Jul 10, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$32→$34
Jun 18, 2026	Baird	Joel Beatty	PT Raise	Outperform	$26→$33
Jun 15, 2026	Needham	Gil Blum	Maintained	Buy	$34
Jun 10, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$32
Jun 9, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$30→$32
Jun 9, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$30→$32
Jun 8, 2026	Jefferies	Roger Song	PT Raise	Buy	$41→$45
Jun 8, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$28→$25
Jun 8, 2026	Needham	Gil Blum	PT Raise	Buy	$26→$34
May 18, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34

Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $34.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.

Benzinga Newsdesk

Nurix Therapeutics Inc

Nurix Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

PRO
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

PRO
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

PRO
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

PRO
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34

PRO
Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

People Also Watch

People Also Watch

Benzinga

Benzinga

Nurix Therapeutics Inc

Nurix Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

PRONeedham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

PROMorgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

PROUBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

PROMizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34

PROTruist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

PRO
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

PRO
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

PRO
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

PRO
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34

PRO
Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34